ALUNBRIG® (brigatinib) Shrank Tumors in Patients With ALK+ NSCLC That Had Spread to Other Parts of the Body
ALUNBRIG was evaluated in a broad range of patients, including those with ALK+ NSCLC that had spread to other parts of their body
The ALUNBRIG study included 275 patients with ALK+ NSCLC whose lung cancer had spread to other parts of their body.
137 patients received the recommended dosing regimen of 90 mg of ALUNBRIG orally once daily for 7 days, followed by an increase to 180 mg orally once daily. The other 138 patients received a different medicine called crizotinib.
- Patient ages ranged from 27 years to 89 years (median age was 59 years) and about half (55%) were female
- 58% of patients in the study had never smoked
Patients taking ALUNBRIG went twice as long without their disease getting worse or spreading versus those taking crizotinib
BLINDED INDEPENDENT REVIEW COMMITTEE RESULTS
MEDIANa TIME TO PROGRESSION
aMedian is not the same as average. Please see glossary for definition
BLINDED INDEPENDENT REVIEW COMMITTEE
This was a group of independent researchers who objectively reviewed and evaluated the results from the trial.
Overall, 3 out of 4 patients (74%) taking ALUNBRIG had their tumors shrink, vs 62% of patients taking crizotinib.
101 of 137 patients (74%) taking ALUNBRIG had their tumors shrink vs 85 of 138 patients (62%) taking crizotinib.
ALUNBRIG Helped Shrink Tumors in the Brain
Additional Study Results
The Blinded Independent Review Committee also evaluated a smaller group of 41 patients with brain metastases.
Overall, 14 of 18 patients (78%) achieved a response while taking ALUNBRIG vs 6 of 23 patients (26%) taking crizotinib
- 3 out of every 4 patients with cancer that spread to their brain saw their tumors shrink when they were treated with ALUNBRIG
More than half of all patients (9 out of 14) who responded to ALUNBRIG maintained that response for 2 years or longer
- Researchers could not estimate the results for the 6 patients who responded to treatment with crizotinib
People Reported a Better Quality of Life with ALUNBRIG
During the study, 131 people taking ALUNBRIG completed a quality of life questionnaire.
Results from the questionnaire showed that people receiving ALUNBRIG went THREE TIMES LONGER without the symptoms of their cancer getting worse compared to patients treated with crizotinib.
- This means that the average time to symptoms getting worse was 26.7 months for patients taking ALUNBRIG compared with 8.3 months for patients taking crizotinib
- The study measurement included how people functioned with the disease (physical, emotional and social functioning) and the severity of the symptoms they experienced
The results of this survey weren't originally a part of the study. Patients also knew which medicine they were taking during the study. This means that patients may have marked their quality-of-life improvements higher than they actually were.
Every patient is different. Always talk to your doctor if you have any questions about ALUNBRIG.
It's normal to have questions as you begin your treatment on ALUNBRIG
We have additional resources for you to discuss with your healthcare provider as you get started.
- Median – The middle number in a set of measurements arranged from lowest to highest.